Pulse Biosciences, Inc. (PLSE)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appro.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 4, 2026, at 1:10 pm ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and P.

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success a.

Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.

Pulse Biosciences Inc. (NASDAQ: PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.

Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $13.69, but opened at $14.95. Pulse Biosciences shares last traded at $18.3250, with a volume of 69,806 shares trading hands. Analysts Set New Price Targets PLSE has been the subject of several

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annu.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated with Abbott's EnSiteX™ 3D Mapping System at the 31st Annual AF Symposium 2026 meeting, being held February 5-7 in Bo.

Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market reversed course and sold off on Thursday, and that could carry over into today. While the major indices ended off their midday lows,... Here Are Friday's Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More.

Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. “We are delighted to welcome Maria to our Board of Directors,” said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. “She brings an exceptionally strong track record.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation at the 31st Annual AF Symposium 2026 meeting in February. This late breaking data will be presented by Vivek Reddy, M.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Pulse Biosciences' Management is scheduled to present on Wednesday, January 14, 2026, at 3:45pm PT. A live and recorded webcast of the presentation will be available.